The authors present two patients with Alzheimer's disease who each
received a single intravenous dose of physostigmine. Subjective complaints
and mood changes were disproportional with objectively verified
physiological side effects. Such observations may contribute to an
understanding of affective disorders and should receive more attention in
future studies of cholinesterase inhibitors.Abstract Teaser